Beta Bionics (BBNX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Beta Bionics

NasdaqGM•Healthcare•Medical Devices

$19.33-0.09(<0.01%)Pre-market

Market Cap

$975.10M

P/S

8.2x

P/B

3.8x

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

How this company scores

WeakMetricSide Score: 38/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (6/25).

Profitability7/25

Growth10/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredConsistent growthNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 8.2x5y range 4.0x – 14.2x

Currently near its 4-quarter median.

P/B · 3.8x5y range 1.2x – 4.9x

Currently above its 6-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 7 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $975.10M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $119.01M
Q. Revenue: $32.01M
TTM EBITDA: $-80.80M
TTM Op. Income: $-83.02M
Q. Op. Income: $-25.58M
TTM Net Income: $-72.97M
Q. Net Income: $-23.40M
EPS: $-0.53
Shares Out.: $44.55M

$119.01M in TTM revenue grew from zero YoY, reaching $32.01M last quarter. TTM EBITDA of $-80.80M and TTM operating income of $-83.02M show growth is flowing through to the bottom line. However, net income is negative at $72.97M — growth is not yet reaching the bottom line. Across the last 7 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 59.0%
EBITDA Margin: -77.7%
Op. Margin: -79.9%
Net Margin: -73.1%

Op. margin of -79.9% is up 5.6% YoY — cost efficiency is improving. Net margin at -73.1% and gross margin of 59.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 7% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 8.2x
P/B Ratio: 3.8x

P/S of 8.2x and P/B of 3.8x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $292.39M
Cash: $44.32M
Long-Term Debt: N/A
Book Value: $256.37M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-14.62M
TTM Free Cash Flow: $-61.41M
FCF Margin: -51.6%
FCF / Net Income: 0.8

TTM FCF of $-61.41M on $-14.62M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 7 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.